RNF

DRUG2 trials

Sponsors

Merck KGaA, Darmstadt, Germany

Conditions

Clinically Isolated SyndromeMultiple Sclerosis

Phase 3

REbif FLEXible Dosing in Early Multiple Sclerosis (MS)

CompletedNCT00404352

Merck KGaA, Darmstadt, GermanyMultiple Sclerosis

Start: 2006-11-30End: 2011-07-31Updated: 2014-01-24

Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX)

CompletedNCT00813709

Merck KGaA, Darmstadt, GermanyClinically Isolated Syndrome, Multiple Sclerosis

Start: 2008-12-31End: 2013-09-30Updated: 2017-03-08

Related Papers

Serum neurofilament light chain correlations in patients with a first clinical demyelinating event in the REFLEX study: a <i>post hoc</i> analysis

Therapeutic Advances in Neurological Disorders2024-01-013 citations

Evolution from a first clinical demyelinating event to multiple sclerosis in the REFLEX trial: Regional susceptibility in the conversion to multiple sclerosis at disease onset and its amenability to subcutaneous interferon beta‐1a

European Journal of Neurology2022-03-118 citations

Subcutaneous interferon β-1a in the treatment of clinically isolated syndromes: 3-year and 5-year results of the phase III dosing frequency-blind multicentre REFLEXION study

Journal of Neurology Neurosurgery & Psychiatry2016-12-3039 citations

Patient subgroup analyses of the treatment effect of subcutaneous interferon β-1a on development of multiple sclerosis in the randomized controlled REFLEX study.

2014-01-1211 citations

Efficacy of subcutaneous interferon -1a on MRI outcomes in a randomised controlled trial of patients with clinically isolated syndromes

Journal of Neurology Neurosurgery & Psychiatry2013-11-2925 citations

Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial.

2011-12-04146 citations